Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 151   

Articles published

NVS 101.49 -0.31 (-0.30%)
price chart
Stock Report on Novartis AG (ADR) (NYSE:NVS)
[CNW Group] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced one-year study results from the MEASURE 2 pivotal Phase III study of investigational secukinumab in ankylosing spondylitis (AS).
Healthcare Stocks in Action: AbbVie Inc. (NYSE:ABBV), GlaxoSmithKline plc ...  StreetWise Report
Latest Alerts: Waste Management (NYSE:WM), AbbVie Inc. (NYSE:ABBV), Novartis ...  Property Mentor
Novartis AG (ADR) (NYSE:NVS) in Focus
[AP] Novartis AG (ADR) (NYSE:NVS) (TREND ANALYSIS) A federal appeals court has ruled that Novartis can begin selling its lower-cost copy of an Amgen Inc. drug in September, rejecting a bid to further delay the launch of the knock-off biotech medication.
Novartis AG (ADR) (NVS) Q2 Profits Eaten By Strengthening Dollar  Bidness ETC
Stocks Posting A Big Cash Outflow: Novartis AG (ADR) (NYSE:NVS), Medtronic ...  Wall Street Observer
General Report on Novartis AG (ADR) (NYSE:NVS)
[Reuters] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S.
Technical Report on Novartis AG (ADR) (NYSE:NVS)
[Zacks] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) announced positive one-year results from a pivotal multi-center, randomized, placebo-controlled phase III study (FUTURE 2) on Cosentyx.
Novartis AG (ADR) (NYSE:NVS) Faces a Huge Fine as a Result of Allegations ...
Technical Insights on Novartis AG (ADR) (NYSE:NVS)
[Bloomberg] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) the world's biggest drugmaker by sales, reported first-quarter profit that beat analysts' estimates as the company begins to benefit from a set of transactions that make it smaller and more ...
Novartis AG (ADR) (NVS) Seeks $2-5 Billion Takeover Targets  Bidness ETC
Novartis Posts Higher Q1 Profit  Benzinga
Novartis AG (ADR) (NYSE:NVS) is All Set to Rule the Immunotherapy Market
Head of Novartis AG (ADR) (NYSE:NVS)'s oncology department Mr. Bill Hinshaw, said in one of his recent webcast briefing that Novartis will be playing an important role in this field and the company is well-positioned to do so.
Stock Insights on Novartis AG (ADR) (NYSE:NVS)
[Bloomberg] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) The U.S. is seeking as much as $3.3 billion from Novartis AG in a suit claiming the company paid kickbacks to increase sales of two prescription drugs.
News Review - Novartis (NVS), DTE (DTE), Apache (APA), Intel (INTC)  Techsonian (press release)
Novartis AG (ADR) (NVS) To Acquire Spinifex
Novartis AG (ADR) (NYSE:NVS) has announced the acquisition of Spinifex Pharmaceuticals, Inc. The acquisition will allow Novartis to gain access to Spinifex's experimental drugs for chronic pain.
Novartis AG (ADR) (NVS) To Acquire Spinifex For $200 Million  Bidness ETC
Novartis to buy privately held Spinifex for $200 mln  Proactive Investors USA & Canada
Novartis AG (ADR) (NYSE:NVS) Adds Spinifex Pharmaceuticals to its Portfolio
Novartis AG ADR (NYSE:NVS) recently announced that it will soon be acquiring a US-Australian biotech company called Spinifex Pharmaceuticals.
Novartis AG (ADR) (NVS) Looks At Performance Based Pricing System Ahead Of ...  InvestCorrectly
Novartis AG (ADR) Expects Higher Profit Margin & Dividends This Year
Novartis AG (ADR) (NYSE:NVS) expects its profit margin to increase in 2015 on the back of a restructured drug portfolio and cost-cutting measures.